Historic production of graphene enhanced cement successfully completed
Highlights Production of 600 tonnes of low-carbon PureGRAPH® enhanced cement successfully completed by one of the UK's largest cement producers Graphene enhanced cement will be used by multiple end users in a range of applications, including...
Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split
NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ: PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary...
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational...
Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Announcement Highlights: Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease . The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was...
Robo.ai Inc. Reaches a $180 Million Financing Agreement with ATW Partners
DUBAI, UAE, Dec. 12, 2025 /PRNewswire/ -- Robo.ai Inc. (NASDAQ: AIIO), a technology platform dedicated to "AI, Smart Device and Smart Asset", today announced that it has entered into definitive agreements with ATW Partners (www.atwpartners.com) for...
Datasea Announces Breakthrough in Acoustic-Driven Brain-Computer Interface Technology
Developing Healthcare and Intelligent Interaction Through Core Acoustic Innovation BEIJING, Dec. 11, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a global technology enterprise specializing in acoustic high-tech...
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter...
European Protected Waveform Consortium Achieves Major Milestone with Successful Over-the-Air Testing
Demonstration underscores Europe's commitment to secure, resilient, multi-orbit military satellite communications SINT-NIKLAAS, Belgium, Dec. 10, 2025 /PRNewswire/ -- ST Engineering iDirect's EU Satcom Centre of Excellence, ST Engineering iDirect...
ALR TECHNOLOGIES TO RELAUNCH THE GLUCURVE PET CGM IN JANUARY 2026
SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces the successful completion of internal manufacturing testing on the GluCurve Pet CGM ("GluCurve")...
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited ("the Company"), listed on Nasdaq, today announced its financial results for the six months ended September 30, 2025, achieving substantial revenue increase and a...